Sealonix

About Sealonix

Based in Bedford, Massachusetts, Sealonix, Inc. is a medical technology company focused on developing and commercializing hemostatic sealants for surgical use. The company was established in January 2023 by serial entrepreneur Amar Sawhney, who serves as the CEO. Sawhney has a significant track record in the medical device industry, having previously founded several successful companies, including Confluent Surgical (acquired by Tyco International), Ocular Therapeutix (which went public), and Augmenix (acquired by Boston Scientific), among others. This background provides Sealonix with a foundation of deep expertise in hydrogel-based medical devices. Sealonix operates in the surgical device market, addressing the challenge of controlling bleeding during surgical procedures, particularly as patients become frailer and present more comorbidities. The company contends that existing hemostatic agents have not kept pace with these evolving patient needs. To address this gap, Sealonix is developing the next generation of hemostatic agents using its proprietary biomaterials, which have been utilized for decades in other medical applications. Its business model centers on the development and eventual sale of these medical devices to healthcare providers and surgical centers. The company is currently in the clinical development phase, financed by venture capital. In May 2023, Sealonix secured $20 million in a Series A financing round led by Excelestar Ventures, with participation from other investors including AMED Ventures, Sparta Group, and J2 Ventures. This capital is intended to fund the growth of the development team, execute clinical trials, and pursue FDA approval for its initial product. The company's first product under development is the PramStat patch, an investigational sealant patch designed to provide rapid hemostasis for abdominopelvic and orthopedic procedures. A key feature of the PramStat patch is that it is designed to be bioabsorbable, resorbing within a week after being implanted during surgery. This aims to reduce the time needed to achieve hemostasis and increase confidence in the durability of the seal.